Annual Report 2013/14 of the Paul-Ehrlich-Institut published
Regulation of biomedicines, research and international key position: these are the key themes of the Annual Report 2013/14 of the Paul-Ehrlich-Institut (PEI). Its unique role as both a research institute and a medicines agency makes the PEI a major player in the development, benefit-risk analysis and assessment of vaccines and biomedicines and positions it as a strong partner in the network of European and international institutions of the health care system.
Is a small artificially composed virus fragment the key to a Chikungunya vaccine?
The mosquito transmitted Chikungunya virus, which causes Chikungunya fever, is spreading continuously. No vaccine is so far available. Researchers of the Paul-Ehrlich-Institut have experimentally recombined segments of the virus surface protein E2, thus creating artificial proteins.
Death for life – The Leishmania parasite needs dead competitors to outwit the immune system
Researchers at the Paul-Ehrlich-Institut have found out how unicellular parasites succeed in tricking our immune system. To be successful, live and dead leishmania parasites must enter the host cells simultaneously. The dead Leishmania are degraded in the cell by means of a self-digestion mechanism (autophagy).